Pharmacoeconomics Evaluation Of The Treatment Of Acute Ischemic Cerebrovascular Disease Of Butylphthalide

Objective: Acute ischemic cerebrovascular disease accounts for approximately 87% of all strokes,the economic burden of diseases caused by stroke to us is as high as 90 billion yuan in the nowadays.There are many kinds of drugs for clinical treatment of acute ischemic cerebrovascular diseases.This study,carried out in the real word,was used to analysis the effects of Butylphthalide on the treatment of patients with acute ischemic cerebrovascular disease in order to provide more scientific evidence for the rational use of Butylphthalide in the treatment of acute ischemic cerebrovascular disease in China.Method: This study,from June 1,2017 to December 31,2018,was conducted on patients with acute ischemic cerebrovascular disease who met the standard of neurology in our hospital.According to the choice of treatment options,the experimental group was divided into the experimental group(Butylphthalide-injection group,Butylphthalide-soft capsule group,Butylphthalide-injection + Butylphthalide-soft capsule sequential group)and the control group(Xue Shuantong-injection +Dan Shenduofensuanyan-injeciton group).This research was performed as a prospective real word observational study and patients were followed for 3 months after discharged.The NIHSS score reduction rate is used as the clinical efficacy index,and the QALYs is used as the quality of life indications,then work out the C/E and ICER.The decision tree model,created by Treeage Pro2011 software,was to observe the stability of study results of each parameter variable via one-way sensitivity analysis and probabilistic sensitivity analysis,and furtherly select the superior treatment of acute ischemic cerebrovascular disease.Result:1.The cost of Illness in the treatment of acute ischemic cerebrovascular disease of Butylphthalide-injection group is 28202.93 yuan,the Butylphthalide-soft capsule group is 23178.80 yuan,the Butylphthalide-injection + Butylphthalide-soft capsule sequential group is 30450.72 yuan and the Xue Shuantong-injection +Dan Shenduofensuanyan-injeciton group is 18915.56 yuan,statistically different.2.The QALYs of Butylphthalide-injection group is 0.1788,the Butylphthalide-soft capsule group is 0.1668,the Butylphthalide-injection + Butylphthalide-soft capsule sequential group is 0.1772 and the Xue Shuantong-injection +Dan Shenduofensuanyan-injeciton group is 0.1664,statistically different.3.The control group has significant pharmacoeconomic advantages.4.Based on the Butylphthalide-soft capsule group,compared with the other 2 experimental groups,the Butylphthalide-injection group is needed 418700 yuan if one QALYs is increased and the Butylphthalide-injection + Butylphthalide-soft capsule sequential group is 699200 yuan.Conclusion:1.Compared with the Butylphthalide-injection group and the Butylphthalide-injection + Butylphthalide-soft capsule sequential group,the Xue Shuantong-injection +Dan Shenduofensuanyan-injeciton group has the significant advantage of pharmacoeconomics of the treatment of acute ischemic cerebrovascular disease,followed by the Butylphthalide-soft capsule group.2.Based on the Butylphthalide-soft capsule group,the ICER of the Butylphthalide-injection group and the Butylphthalide-injection + Butylphthalide-soft capsule sequential group exceed the 3-times per-captia-GDP in China in 2018,that could not be the preferred recommendation for Butylphthalide-durg treatment.